An interplay between genetic and early environmental factors contributes to the development of substance abuse.
Results of the first global survey of psychiatrists on the impact of future autonomous technology.
The novel combination drug is designed to mitigate the weight gain associated with olanzapine.
The first therapy to target the primary mechanism of the disease is safe and well tolerated, say study investigators.
The fallout from burnout: alcohol dependence, binge eating, sleep disorders, and general ill health.
Recent findings could pave the way for targeted therapies for conditions associated with hypervigilance and recurrent distressing memories.
Phase 2 trial results suggest the possibility of a treatment that may regenerate brain cells following TBI.
A novel neuromodulatory intervention for an often-overlooked but nonetheless damaging effect of schizophrenia.